Ranked #1,703 of 8,699 institutional investors
Fairmount Funds Management LLC
West Conshohocken, PA
$1.68B
US stock portfolio at live prices · today +$32.0M (+1.94%)
Market closed. Prices as of Nov 20, 8:41 AM ET
- Value at quarter end (Q3 2026)
- $1.59B
- Change from Q2 2026
- +$81.6M (+5.39%)
- Positions
- 10 · 1 new, 0 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$238M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesORKA 21.5%KRSA 19.2%DNTH 12.8%VRDN 9.52%COGT 9.08%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| ORKA Oruka Therapeutics, Inc. | 3,705,262 | $362M | 21.5% | Unchanged |
| KRSA Korsana Biosciences, Inc. | 9,103,729 | $323M | 19.2% | New |
| DNTH Dianthus Therapeutics, Inc. | 2,537,191 | $215M | 12.8% | Unchanged |
| VRDN Viridian Therapeutics, Inc. | 5,090,928 | $160M | 9.52% | Unchanged |
| COGT Cogent Biosciences, Inc. | 5,503,418 | $153M | 9.08% | Unchanged |
| ELVN Enliven Therapeutics, Inc. | 1,855,644 | $86.1M | 5.12% | Unchanged |
| JBIO Jade Biosciences, Inc. | 4,553,494 | $68.6M | 4.08% | Unchanged |
| ZBIO Zenas BioPharma, Inc. | 2,371,358 | $59.4M | 3.53% | Added +1% |
| IKT Inhibikase Therapeutics, Inc. | 8,625,000 | $11.2M | 0.67% | Unchanged |
| FTH Faeth Therapeutics, Inc. | 722,020 | $6.3M | 0.37% | Unchanged |